Biotech firm BTG’s most important pipeline product, a varicose vein treatment called Varisolve, is safe for use in patients with a common heart defect, according to preliminary trial results. Full story…

« Change Is Good For IntegraMed
Sclerotherapy now the number two most performed cosmetic surgical procedure thanks to men »

This entry was posted on Friday, March 21st, 2008 at 1:30 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Responses are currently closed, but you can trackback from your own site.